Tonix Pharmaceuticals Holding (FRA:TPM0) Profitability Rank: 0 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:TPM0 Tonix Pharmaceuticals Holding Corp FRA:TPM0
26 GF Score
Price €9.46
GF Value €0.37
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Tonix Pharmaceuticals Holding Profitability Rank?

Tonix Pharmaceuticals Holding has the Profitability Rank of 0.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is rated on a scale of 1 to 10 and is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Tonix Pharmaceuticals Holding's Operating Margin % for the quarter that ended in Jun. 2026 was -314.05%. As of today, Tonix Pharmaceuticals Holding's Piotroski F-Score is 4.


Tonix Pharmaceuticals Holding Profitability Rank Related Terms


FRA:TPM0 vs RNA, NERV, GLSI: Profitability Rank Comparison

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tonix Pharmaceuticals Holding Profitability Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Profitability Rank falls into.


FRA:TPM0
26GF Score
Tonix Pharmaceuticals Holding Corp FRA:TPM0
Profitability Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tonix Pharmaceuticals Holding Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The rank is rated on a scale of 1 to 10. A higher score indicates superior profitability, with companies rated 7 or above considered to have more robust and sustainable profit generation. Conversely, a score of 3 or lower suggests challenges in generating consistent profits.

Tonix Pharmaceuticals Holding has the Profitability Rank of 0.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Tonix Pharmaceuticals Holding's Operating Margin % for the quarter that ended in Jun. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2026 ) / Revenue (Q: Jun. 2026 )
=-33.619116200758 / 10.705003169697
=-314.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Tonix Pharmaceuticals Holding has an F-score of 4 indicating the company's financial situation is typical for a stable company.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank

Is Tonix Pharmaceuticals Holding (FRA:TPM0) Overvalued in 2026?

Based on GuruFocus' analysis, Tonix Pharmaceuticals Holding stock appears to be overvalued. The current stock price of €9.46 is trading 2456.2% above its estimated GF Value™ of €0.37. GuruFocus considers Tonix Pharmaceuticals Holding to be Significantly Overvalued.

Key valuation signals for FRA:TPM0:

  • Profitability Rank: 0
  • GF Value™: €0.37 vs. price of €9.46 (2456.2% above fair value)
  • GF Score™: 26/100 with 2 warning signs

No single metric tells the full story. See the FRA:TPM0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tonix Pharmaceuticals Holding Business Description

Other Exchanges TNXP:USA
Address 200 Connell Drive, Suite 3100, Berkeley Heights, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
26GF Score

Get the complete analysis for FRA:TPM0

Profitability Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.46
Price
€0.37
GF Value